Reports Q2 cash and cash equivalents of $26.4M. The company expects its cash runway to be sufficient to fund operations into 2026. “We are excited to announce updated OS and PFS data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients in the coming weeks. Last quarter we reported an exceptional 94% OS observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP. To put that in perspective, in the pivotal study of standard of care GnP, the 6-month OS was only 67%, and dropped rapidly to only 50% by 8.5 months,” said Ben Zeskind, co-founder and CEO of Immuneering (IMRX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering granted atebimetinib patent by USPTO
- Immuneering price target raised to $10 from $8 at Mizuho
- Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
- Immuneering Announces Promising Phase 2a Trial Results